Back to results
US 11,298,378 B2Granted
Materials and methods for engineering cells and uses thereof in immuno-oncology
AssigneeCrispr Therapeutics AG
InventorsJonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Life of this patent
Estimating the term…
Abstract
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Claims29
A method for treating a BCMA+ cancer, comprising administering to a subject in need thereof an effective amount of a population of engineered human T cells,
- wherein the engineered human T cells express a chimeric antigen receptor (CAR) that binds B-cell maturation antigen (BCMA),
- wherein the CAR comprises an ectodomain comprising an anti-BCMA single-chain variable fragment (scFv), and
- wherein the anti-BCMA scFv comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 1524, or 1589, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 1526, 1527, or 1590.
2 more elements
Dependencies are inferred from the claim text.